Emicizumab prophylaxis in people with Hemophilia A and inhibitors: a systematic review and meta-analysis
Keywords:
Hemophilia A, Antibodies, monoclonal, humanized, Blood coagulation factors, Emicizumab, Inhibitors, Prophylaxis, Annualized bleeding rate, Bypassing agentsAbstract
BACKGROUND: Until recently, the treatment of people with hemophilia A and inhibitors (PwHAi) was based on the use of bypassing agents (BPA). However, the advent of emicizumab as prophylaxis has demonstrated promising results. OBJECTIVES: We aimed to compare the bleeding endpoints between PwHAi on BPA and those on emicizumab prophylaxis. DESIGN AND SETTING: Systematic review of interventions and meta-analysis conducted at the Universidade Federal de Goiás, Goiânia, Goiás, Brazil. METHODS: The CENTRAL, MEDLINE, Scopus, and LILACS databases were searched on February 21, 2023. Two authors conducted the literature search, publication selection, and data extraction. The selected publications evaluated the bleeding endpoints between PwHAi on emicizumab prophylaxis and those on BPA prophylaxis. The risk of bias was evaluated according to the Joanna Briggs Institute criteria. A meta-analysis was performed to determine the annualized bleeding rate (ABR) for treated bleeds. RESULTS: Five publications (56 PwHAi) were selected from the 543 retrieved records. Overall, bleeding endpoints were lower during emicizumab prophylaxis than during BPA prophylaxis. All the publications had at least one risk of bias. The only common parameter for the meta-analysis was the ABR for treated bleeds. During emicizumab prophylaxis, the ABR for treated bleeds was lower than during BPA prophylaxis (standard mean difference: −1.58; 95% confidence interval −2.50, −0.66, P = 0.0008; I2 = 68.4%, P = 0.0031). CONCLUSION: Emicizumab was superior to BPA in bleeding prophylaxis in PwHAi. However, both the small population size and potential risk of bias should be considered when evaluating these results. SYSTEMATIC REVIEW REGISTRATION: CRD42021278726, https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=278726.
Downloads
References
Mehta P, Reddivari AKR. Hemophilia. In: Mehta P, Reddivari AKR. StatPearls. Treasure Island: StatPearls Publishing; 2023. PMID: 31869071. Available at: https://www.ncbi.nlm.nih.gov/books/NBK551607/. Accessed in 2023 (March 30).
Ljung R, Auerswald G, Benson G, et al. Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult‐to‐treat patients. Eur J Haematol. 2019;102(2):111-22. PMID: 30411401; https://doi.org/10.1111/ejh.13193.
Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol. 2013;4(1):59-72. PMID: 23610614; https://doi.org/10.1177/2040620712464509.
Morfini M, Haya S, Tagariello G, et al. European Study on Orthopaedic Status of haemophilia patients with inhibitors. Haemophilia. 2007;13(6):606-12. PMID: 17880451; https://doi.org/10.1111/j.1365-2516.2007.01518.x.
Soucie JM, Ciafrini C, Janco RL, et al. Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood. 2004;103(7):2467-73. PMID: 14615381; https://doi.org/10.1182/blood-2003-05-1457.
Kreuz W, Ettingshausen CE. Inhibitors in patients with haemophilia A. Thromb Res. 2014;134(s1):s22-6. PMID: 24745722; https://doi.org/10.1016/j.thromres.2013.10.016.
Carcao M, Escuriola‐Ettingshausen C, Santagostino E, et al. The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab. Haemophilia. 2019;25(4):676-84. MID: 31033112; https://doi.org/10.1111/hae.13762.
Shapiro AD, Mitchell IS, Nasr S. The future of bypassing agents for hemophilia with inhibitors in the era of novel agents. J Thromb Haemost. 2018;16(12):2362-74. PMID: 30264916; https://doi.org/10.1111/jth.14296.
Astermark J, Donfield SM, DiMichele DM, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 2007;109(2):546-51. PMID: 16990605; https://doi.org/10.1182/blood-2006-04-017988.
Knight T, Callaghan MU. The role of emicizumab, a bispecific factor IXa- and factor X-directed antibody, for the prevention of bleeding episodes in patients with hemophilia A. Ther Adv Hematol. 2018;9(10):319-34. PMID: 30344994; https://doi.org/10.1177/2040620718799997.
Kitazawa T, Igawa T, Sampei Z, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012;18(10):1570-4. PMID: 23023498; https://doi.org/10.1038/nm.2942.
Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017;377(9):809-18. PMID: 28691557; https://doi.org/10.1056/nejmoa1703068.
Young G, Liesner R, Chang T, et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019;134(24):2127-38. PMID: 31697801; https://doi.org/10.1182/blood.2019001869.
Shima M, Hanabusa H, Taki M, et al. Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors. Blood Adv. 2017;1(22):1891-9. PMID: 29296836; https://doi.org/10.1182/bloodadvances.2017006684.
Pipe SW, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. 2019;6(6):e295-305. PMID: 31003963; https://doi.org/10.1016/s2352-3026(19)30054-7.
Higgins JPT, Thomas J, Chandler J, et al., eds. Cochrane Handbook for Systematic Reviews of Interventions. Wiley; 2019. http://doi.org/10.1002/9781119536604.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. J Clin Epidemiol. 2021;134:178-89. PMID: 33789819; https://doi.org/10.1016/j.jclinepi.2021.03.001.
Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. PMID: 27919275; https://doi.org/10.1186/s13643-016-0384-4.
Aromataris E, Munn Z, edits. JBI Manual for Evidence Synthesis. JBI, 2020. https://doi.org/10.46658/JBIMES-20-01.
Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13. PMID: 15840177; https://doi.org/10.1186/1471-2288-5-13.
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-60. PMID: 12958120; https://doi.org/10.1136/bmj.327.7414.557.
Cochran WG. The Combination of Estimates from Different Experiments. Biometrics. 1954;10(1):101-29. https://doi.org/10.2307/3001666.
The R Foundation. R: A language and environment for statistical computing. 2021. Available at: https://www.r-project.org/. Accessed in 2023 (March 30).
Shima M, Nagao A, Taki M, et al. Long‐term safety and efficacy of emicizumab for up to 5.8 years and patients’ perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A. Haemophilia. 2021;27(1):81-9. PMID: 33236410; https://doi.org/10.1111/hae.14205.
Misgav M, Brutman‐Barazani T, Budnik I, et al. Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: real‐world data. Haemophilia. 2021;27(2):253-60. PMID: 33595174; https://doi.org/10.1111/hae.14261.
McCary I, Guelcher C, Kuhn J, et al. Real‐world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures. Haemophilia. 2020;26(4):631-6. PMID: 32311809; https://doi.org/10.1111/hae.14005.
Barg AA, Livnat T, Budnik I, et al. Emicizumab treatment and monitoring in a paediatric cohort: real‐world data. Br J Haematol. 2020;191(2):282-90. PMID: 32656767; https://doi.org/10.1111/bjh.16964.
Barg AA, Avishai E, Budnik I, et al. Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors—a single‐center cohort. Pediatr Blood Cancer. 2019;66(11):e27886. PMID: 31348595; https://doi.org/10.1002/pbc.27886.
Barg AA, Budnik I, Avishai E, et al. Emicizumab prophylaxis: Prospective longitudinal real‐world follow‐up and monitoring. Haemophilia. 2021;27:383-91. PMID: 33892524; https://doi.org/10.1111/hae.14318.
Warren BB, Chan A, Manco‐Johnson M, et al. Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: a single‐center report. Res Pract Thromb Haemost. 2021;5(5):e12571. PMID: 34377887; https://doi.org/10.1002/rth2.12571.
Ebbert PT, Xavier F, Seaman CD, Ragni MV. Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors. Haemophilia. 2020;26(1):41-6. PMID: 31746522; https://doi.org/10.1111/hae.13877.
Cafuir L, Kruse-Jarres R, Mancuso ME, Kempton CL. Emicizumab for hemophilia A without inhibitors. Expert Rev Hematol. 2019;12(7):515-24. PMID: 31130012; https://doi.org/10.1080/17474086.2019.1624519.
Makris M, Iorio A, Lenting PJ. Emicizumab and thrombosis: the story so far. J Thromb Haemost. 2019;17(8):1269-72. PMID: 31368220; https://doi.org/10.1111/jth.14556.
Gundabolu K, Goldsweig A, Bhatt VR, Koepsell SA, Harper JL. ST‐segment elevation myocardial infarction (STEMI) and pulmonary embolism in a hemophilia A patient receiving emicizumab and recombinant activated factor VII. Haemophilia. 2020;26(1):e5-e8. PMID: 31694063; https://doi.org/10.1111/hae.13871.
Harkins Druzgal C, Kizilocak H, Brown J, Sennett M, Young G. Neutralizing antidrug antibody to emicizumab in a patient with severe hemophilia A with inhibitors: new case with detailed laboratory evaluation. J Thromb Haemost. 2020;18(9):2205-8. PMID: 32544268; https://doi.org/10.1111/jth.14957.
Paz-Priel I, Chang T, Asikanius E, et al. Immunogenicity of emicizumab in people with hemophilia A (PwHA): results from the HAVEN 1-4 studies. Blood. 2018;132(suppl. 1):633. https://doi.org/10.1182/blood-2018-99-118492.
Gagnier JJ, Moher D, Boon H, Beyene J, Bombardier C. Investigating clinical heterogeneity in systematic reviews: a methodologic review of guidance in the literature. BMC Med Res Methodol. 2012;12:111. PMID: 22846171; https://doi.org/10.1186/1471-2288-12-111.
Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L, Moreno SG. Assessing Publication Bias in Meta-Analyses in the Presence of Between-Study Heterogeneity. J R Stat Soc Ser A Stat Soc. 2010;173(3):575-91. https://doi.org/10.1111/j.1467-985X.2009.00629.x.
van Velzen AS, Eckhardt CL, Streefkerk N, et al. The incidence and treatment of bleeding episodes in non-severe haemophilia A patients with inhibitors. Thromb Haemost. 2016;115(3):543-50. PMID: 26582077; https://doi.org/10.1160/th15-03-0212.
Teitel J, Berntorp E, Collins P, et al. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia. 2007;13(3):256-63. PMID: 17498074; https://doi.org/10.1111/j.1365-2516.2007.01449.x.
duTreil S. Physical and psychosocial challenges in adult hemophilia patients with inhibitors. J Blood Med. 2014;5:115-22. PMID: 25093002; https://doi.org/10.2147/jbm.s63265.
López-Fernández MF, Roca CA, Álvarez-Román MT, et al. Spanish Consensus Guidelines on prophylaxis with bypassing agents in patients with haemophilia and inhibitors. Thromb Haemost. 2016;115(5):872-95. PMID: 26842562; https://doi.org/10.1160/th15-07-0568.
Chai-Adisaksopha C, Nevitt SJ, Simpson ML, Janbain M, Konkle BA. Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors. Cochrane Database Syst Rev. 2017;9(9):CD011441. PMID: 28944952; https://doi.org/10.1002/14651858.cd011441.pub2.
Mahlangu J, Oldenburg J, Callaghan MU, et al. Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: a prospective, multi-centre, non-interventional study. Haemophilia. 2018;24(6):921-9. PMID: 30295389; https://doi.org/10.1111/hae.13612.
Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia. 2009;15(1):3-10. PMID: 19016901; https://doi.org/10.1111/j.1365-2516.2008.01931.x.
Shima M, Takedani H, Kitsukawa K, et al. AOZORA: long-term safety and joint health in paediatric persons with haemophilia A without factor VIII inhibitors receiving emicizumab – protocol for a multicentre, open-label, phase IV clinical study. BMJ Open. 2022;12(6):e059667. PMID: 35697445; https://doi.org/10.1136/bmjopen-2021-059667.
Kiialainen A, Niggli M, Kempton CL, et al. Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study. Haemophilia. 2022;28(6):1033-43. PMID: 35905294; https://doi.org/10.1111/hae.14642.
Oldenburg J, Mahlangu JN, Bujan W, et al. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 study. Haemophilia. 2019;25(1):33-44. PMID: 30427582; https://doi.org/10.1111/hae.13618.
Mahlangu J, Oldenburg J, Callaghan MU, et al. Health‐related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non‐interventional study (NIS). Haemophilia. 2019;25(3):382-91. PMID: 31016855; https://doi.org/10.1111/hae.13731.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 São Paulo Medical Journal
This work is licensed under a Creative Commons Attribution 4.0 International License.
